The present invention provides microneedles and microneedle array patch (100) for drug delivery and production method thereof. In particular, the present invention provides a microneedle array patch (100) for drug delivery comprising: (a) a backing layer (103); (b) a plurality of dissolvable polymeric microneedles (102) fixed to said backing layer (103), said polymeric microneedles (102) being made up of polyvinyl alcohol (PVA) and gelatin, said polymeric microneedles (102) being fixed to and extending from an adhesive surface provided on the backing layer (103); and (c) drug loaded nanocarriers (101) entrapped within the matrix of said polymeric microneedles (102) for delivery by said polymeric microneedles (102) into skin; wherein said drug loaded nanocarriers (101) are selected from the group consisting of lipid nanocarriers or polymeric nanocarriers. The present invention also provides a method of producing the afore-mentioned microneedle array patch (100) for drug delivery.

The disclosure provides new transdermal pharmaceutical compositions comprising 1-(4-fluoro-phenyl)-4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H,7H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8-yl)-butan-1-one or 1-(4-fluoro-phenyl)-4-((6bR,10aS)-2,2-d.sub.2-3-methyl-2,3,6b,9,10,10a-hexahydro-1H,7H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8-yl)-butan-1-one or comprising -(4-fluoro-phenyl)-4-((6bR,10aS)-1,1,2,2-d.sub.4-3-methyl-2,3,6b,9,10,10a-hexahydro-1H,7H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8-yl)-butan-1-one, in free base, co-crystal or salt form, together with methods of making and using them.

A method of administering a pharmaceutical agent to the circulatory system through the skin of a mammal may include the steps of loading a pharmaceutical agent in a transdermal patch, applying the transdermal patch to the skin of the mammal and releasing the pharmaceutical agent into the circulatory system at a rate of at least 0.001 micrograms per hour up to 50.0 micrograms per hour per kilogram of bodyweight of the mammal. The drug delivery system may comprise a transdermal patch loaded with the pharmaceutical agent. The patch may include a porous membrane and an outer impermeable cover defining a cavity therebetween. A plurality of drug delivery layers may be disposed between the porous membrane and the impermeable cover. A lipophilic/hydrophilic suspension may be disposed between the drug delivery layers.

Transdermal delivery devices for the delivery of cannabidiol (CBD) are shown and described. In reservoir patch designs, a microporous, hydrophilic membrane and a backing define a reservoir that houses a mixture of CBD, a polar liquid, and a gelling agent. The hydrophilic membrane is coated with an amine-compatible silicone skin adhesive. In a monolithic design, a release liner is coated with a mixture of CBD and a PIB or amine-compatible silicone skin adhesive laminated to the backing material. In either design, the CBD may be provided as a pure compound or as a component of a Cannabis oil.

The present disclosure relates to compositions methods of use and methods of manufacturing, hydrous hydrogel compositions useful as topical oral analgesics including cannabinoids and menthol.

An iontophoretic patch for transdermal delivery of biologically active agents includes at least two electrodes in contact with at least two hydrogel reservoirs. At least one of the hydrogel reservoirs carries at least one active agent and, in use of the iontophoretic patch, is disposed on a user's skin and delivers at least one active agent into the skin. The patch includes a control unit to generate a stimulation pattern having stimulation parameters delivered to stimuli locations on the skin. A stimulation unit generates a time sequence of pulses from the stimulation parameters generated by the control unit. The patch further includes a demultiplexing unit configured to perform independent spatio-temporal distribution of the electrical pulses in the time sequence of pulses to at least one electrode; at least one optical sensing system, for continuously measuring an amount of the active agent in the hydrogel reservoir; and a feedback unit.

Modulators of melanocortin receptors (MCR) are provided herein. An MC5R peptide ligand is represented by to Formula 1:
R.sub.1-Nle.sup.4-c[Xaa.sup.5-Yaa.sup.6-(NMe)D-Nal(2′).sup.7-Arg.sup.8-Trp.sup.9-(NMe)Zaa.sup.10]-R.sub.2.
R.sub.1 can be an acetyl, a glycosylated amino acid, —CO—(CH.sub.2).sub.nCH.sub.3, or —CO—(CH.sub.2).sub.nCF.sub.3 with n ranging from 1 to 6. R.sub.2 can be an —CONH.sub.2, —COOH, or —CH.sub.2OH. Xaa, Yaa, and Zaa can each be a natural amino acid or an unnatural amino acid.

A transdermal delivery system for systemic delivery of donepezil is described, where the system comprises an adhesive matrix drug reservoir layer comprised of a copolymer of acrylic acid/vinyl acetate, triethyl citrate, and donepezil base generated in situ by reaction of donepezil HCl and an alkaline salt. The system is provided for treatment of Alzheimer's disease, and achieves transdermal delivery of the therapeutic agent at steady state that is bioequivalent to administration of the therapeutic agent orally.

The invention provides compositions, methods and kits for the removal of harmful or irritating substances from bodily surfaces. Kits may include a composition containing capsaicin and a capsaicin-cleansing composition, e.g., a composition in which capsaicin is soluble.

Among other things, the present disclosure provides compositions and methods for an elastomeric cross-linked polyester material. Such an elastomeric cross-linked polyester material, in some embodiments, comprises a plurality of polymeric units of the general formula (-A-B-).sub.p, wherein p is an integer greater than 1; and a plurality of urethane cross-links each of which covalently links two polymeric units to one another, which two linked polymeric unit each had at least one free hydroxyl or amino group prior to formation of the crosslink.